MedTrace Logo

Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib

NCT05682924 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2024-12-16

No results posted yet for this study

Summary

The study will study the state of the endothelium in patients with chronic myeloid leukemia during therapy with the II generation tyrosine kinase inhibitor bosutinib. Patients will be divided into groups receiving nilotinib 800mg/day, bosutinib 500mg/day, and imatinib 600mg/day. A comprehensive examination of patients will be carried out, including a clinical examination, a study of biochemical markers of endothelial damage and the functional state of the vascular wall. An algorithm will be developed for assessing the state of endothelial function in patients with ph-positive chronic myeloid leukemia in the chronic phase when using the second-generation tyrosine kinase inhibitor bosutinib.

Conditions

  • Chronic Myeloid Leukaemia

Interventions

DIAGNOSTIC_TEST

taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry

In the study, blood will be taken from patients with chronic myelogenous leukemia in the chronic phase to determine biochemical parameters (endothelin-1, homocysteine, VEGF (vascular endothelial growth factor)), as well as a study of microcirculation in these groups of patients using the method of laser Doppler flowmetry, to study the function of the endothelium.

Sponsors & Collaborators

  • Samara State Medical University

    lead OTHER

Principal Investigators

  • Sabina Cherenova · Samara State Medical University

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2025-09-01
Completion
2025-09-15

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05682924 on ClinicalTrials.gov